The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

FDA approves experimental stem cell therapy to help deaf ear repair itself

| May 15, 2012

The Food and Drug Administration (FDA) has recently approved a groundbreaking trial by the University of Texas Medical School at Houston to evaluate the safety of using a child’s own cord blood stem cells to regenerate damaged cells in the inner ear and potentially restore the child’s hearing. Just as antibiotics changed the treatment of infections, stem cells may revolutionize the future of nervous system repair.

View the original article here: FDA approves experimental stem cell therapy to help deaf ear repair itself

The GLP featured this article to reflect the diversity of news, opinion and analysis. The viewpoint is the author’s own. The GLP’s goal is to stimulate constructive discourse on challenging science issues.

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend